Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.18M
2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 42K
3: EX-10.27 Material Contract HTML 92K
4: EX-10.28 Material Contract HTML 102K
5: EX-21.1 Subsidiaries List HTML 26K
6: EX-23.1 Consent of Experts or Counsel HTML 30K
7: EX-24.1 Power of Attorney HTML 33K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 32K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
95: R1 Document And Entity Information HTML 67K
42: R2 Consolidated Balance Sheets HTML 133K
31: R3 Consolidated Balance Sheets (Parentheticals) HTML 48K
64: R4 Consolidated Statements of Operations HTML 109K
94: R5 Consolidated Statements of Comprehensive Loss HTML 38K
41: R6 Consolidated Statements of Stockholders' (Deficit) HTML 125K
Equity
30: R7 Consolidated Statements of Stockholders' (Deficit) HTML 30K
Equity (Parentheticals)
62: R8 Consolidated Statements of Cash Flows HTML 112K
97: R9 Note 1 - Organization and Summary of Significant HTML 127K
Accounting Policies
55: R10 Note 2 - Liquidity HTML 43K
24: R11 Note 3 - Discontinued Operations HTML 33K
72: R12 Note 4 - Revenue From Contracts With Customers HTML 100K
82: R13 Note 5 - Fair Value HTML 54K
54: R14 Note 6 - Stock-based Compensation HTML 70K
23: R15 Note 7 - Loss Per Share HTML 33K
71: R16 Note 8 - Accounts and Other Receivables and HTML 41K
Concentrations of Credit Risk
81: R17 Note 9 - Property and Equipment HTML 48K
53: R18 Note 10 - Investment in Macrophage Therapeutics, HTML 57K
Inc.
25: R19 Note 11 - Accounts Payable, Accrued Liabilities HTML 40K
and Other
57: R20 Note 12 - Notes Payable HTML 53K
89: R21 Note 13 - Leases HTML 69K
38: R22 Note 14 - Commitments and Contingencies HTML 73K
27: R23 Note 15 - Equity Instruments HTML 66K
56: R24 Note 16 - Income Taxes HTML 130K
88: R25 Note 17 - Segments HTML 144K
37: R26 Note 18 - Agreements HTML 43K
26: R27 Note 19 - Employee Benefit Plan HTML 32K
58: R28 Note 20 - Supplemental Disclosure for Statements HTML 34K
of Cash Flows
87: R29 Note 21 - Subsequent Events HTML 34K
84: R30 Significant Accounting Policies (Policies) HTML 177K
74: R31 Note 1 - Organization and Summary of Significant HTML 44K
Accounting Policies (Tables)
21: R32 Note 4 - Revenue From Contracts With Customers HTML 75K
(Tables)
51: R33 Note 5 - Fair Value (Tables) HTML 46K
85: R34 Note 6 - Stock-based Compensation (Tables) HTML 64K
75: R35 Note 8 - Accounts and Other Receivables and HTML 38K
Concentrations of Credit Risk (Tables)
22: R36 Note 9 - Property and Equipment (Tables) HTML 46K
52: R37 Note 11 - Accounts Payable, Accrued Liabilities HTML 36K
and Other (Tables)
86: R38 Note 13 - Leases (Tables) HTML 63K
73: R39 Note 15 - Equity Instruments (Tables) HTML 44K
90: R40 Note 16 - Income Taxes (Tables) HTML 117K
60: R41 Note 17 - Segments (Tables) HTML 137K
34: R42 Note 1 - Organization and Summary of Significant HTML 111K
Accounting Policies (Details Textual)
44: R43 Note 1 - Organization and Summary of Significant HTML 53K
Accounting Policies - Assumptions Used to
Calculate Fair Value of Stock Option Awards
Granted (Details)
91: R44 Note 2 - Liquidity (Details Textual) HTML 80K
61: R45 Note 3 - Discontinued Operations (Details Textual) HTML 37K
36: R46 Note 4 - Revenue From Contracts With Customers HTML 66K
(Details Textual)
45: R47 Note 4 - Revenue From Contracts With Customers - HTML 38K
Change in Deferred Revenue and Accumulated Deficit
(Details)
92: R48 Note 4 - Revenue From Contracts With Customers - HTML 43K
Disaggregation of Revenue (Details)
59: R49 Note 4 - Revenue From Contracts With Customers - HTML 37K
Changes in Contract Liabilities (Details)
67: R50 Note 5 - Fair Value (Details Textual) HTML 31K
78: R51 Note 5 - Fair Value - Financial Liabilities HTML 43K
Measured at Fair Value on a Recurring Basis
(Details)
50: R52 Note 6 - Stock-based Compensation (Details HTML 67K
Textual)
20: R53 Note 6 - Stock-based Compensation - Summary of HTML 60K
Stock Option Activity (Details)
66: R54 Note 6 - Stock-based Compensation - Summary of HTML 44K
Unvested Restricted Stock (Details)
77: R55 Note 7 - Loss Per Share (Details Textual) HTML 32K
49: R56 Note 8 - Accounts and Other Receivables and HTML 38K
Concentrations of Credit Risk (Details Textual)
19: R57 Note 8 - Accounts and Other Receivables and HTML 35K
Concentrations of Credit Risk - Accounts and Other
Receivables (Details)
68: R58 Note 9 - Property and Equipment (Details Textual) HTML 28K
76: R59 Note 9 - Property and Equipment - Summary of Major HTML 48K
Classes of Property and Equipment (Details)
43: R60 Note 10 - Investment in Macrophage Therapeutics, HTML 105K
Inc. (Details Textual)
32: R61 Note 11 - Accounts Payable, Accrued Liabilities HTML 34K
and Other (Details Textual)
65: R62 Note 11 - Accounts Payable, Accrued Liabilities HTML 35K
and Other - Accrued Liabilities and Other
(Details)
96: R63 Note 12 - Notes Payable (Details Textual) HTML 147K
40: R64 Note 13 - Leases (Details Textual) HTML 61K
29: R65 Note 13 - Leases - Impact of the Adoption of ASU HTML 42K
2016-02 on Our Balance Sheet (Details)
63: R66 Note 13 - Leases - Amount, Timing and Uncertainty HTML 57K
of Cash Flows Arising From Operating Leases
(Details)
93: R67 Note 14 - Commitments and Contingencies (Details HTML 102K
Textual)
39: R68 Note 15 - Equity Instruments (Details Textual) HTML 165K
33: R69 Note 15 - Equity Instruments - Outstanding HTML 45K
Warrants (Details)
17: R70 Note 16 - Income Taxes (Details Textual) HTML 59K
46: R71 Note 16 - Income Taxes - Components of Deferred HTML 52K
Tax Assets (Details)
79: R72 Note 16 - Income Taxes - Net Operating Loss and HTML 102K
Credit Carryforwards (Details)
69: R73 Note 16 - Income Taxes - Reconciliations Between HTML 56K
the Statutory Federal Income Tax Rate and the
Effective Tax Rate (Details)
18: R74 Note 17 - Segments (Details Textual) HTML 38K
47: R75 Note 17 - Segments - Segment Information (Details) HTML 117K
80: R76 Note 18 - Agreements (Details Textual) HTML 71K
70: R77 Note 19 - Employee Benefit Plan (Details Textual) HTML 28K
16: R78 Note 20 - Supplemental Disclosure for Statements HTML 66K
of Cash Flows (Details Textual)
48: R79 Note 21 - Subsequent Events (Details Textual) HTML 46K
35: XML IDEA XML File -- Filing Summary XML 178K
83: EXCEL IDEA Workbook of Financial Reports XLSX 93K
10: EX-101.INS XBRL Instance -- navb-20191231 XML 2.75M
12: EX-101.CAL XBRL Calculations -- navb-20191231_cal XML 141K
13: EX-101.DEF XBRL Definitions -- navb-20191231_def XML 2.14M
14: EX-101.LAB XBRL Labels -- navb-20191231_lab XML 1.49M
15: EX-101.PRE XBRL Presentations -- navb-20191231_pre XML 2.10M
11: EX-101.SCH XBRL Schema -- navb-20191231 XSD 274K
28: ZIP XBRL Zipped Folder -- 0001437749-20-005567-xbrl Zip 259K
‘EXCEL’ — IDEA Workbook of Financial Reports
This is an IDEA Workbook.
16 Subsequent Filings that Reference this Filing
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent
12/26/23 Navidea Biopharmaceuticals, Inc. S-8 12/26/23 4:70K RDG Filings/FA
4/28/23 Navidea Biopharmaceuticals, Inc. 424B5 1:505K RDG Filings/FA
3/27/23 Navidea Biopharmaceuticals, Inc. 10-K 12/31/22 91:10M RDG Filings/FA
8/02/22 Navidea Biopharmaceuticals, Inc. S-1/A 15:1.9M RDG Filings/FA
7/20/22 Navidea Biopharmaceuticals, Inc. S-1/A 13:1.6M RDG Filings/FA
7/01/22 Navidea Biopharmaceuticals, Inc. S-1/A 2:1M RDG Filings/FA
3/28/22 Navidea Biopharmaceuticals, Inc. 10-K 12/31/21 90:10M RDG Filings/FA
2/14/22 Navidea Biopharmaceuticals, Inc. S-1 2/11/22 3:944K RDG Filings/FA
5/13/21 Navidea Biopharmaceuticals, Inc. S-1 3:378K RDG Filings/FA
3/26/21 Navidea Biopharmaceuticals, Inc. 10-K 12/31/20 93:9.8M RDG Filings/FA
2/08/21 Navidea Biopharmaceuticals, Inc. S-3 4:908K RDG Filings/FA
11/13/20 Navidea Biopharmaceuticals, Inc. S-8 11/13/20 4:1.7M RDG Filings/FA
9/02/20 Navidea Biopharmaceuticals, Inc. 424B5 1:511K RDG Filings/FA
9/02/20 Navidea Biopharmaceuticals, Inc. 424B5 1:546K RDG Filings/FA
8/25/20 Navidea Biopharmaceuticals, Inc. S-3 4:401K RDG Filings/FA
8/11/20 Navidea Biopharmaceuticals, Inc. 424B5 1:576K RDG Filings/FA
|
↑Top
Filing Submission 0001437749-20-005567 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Mon., Apr. 29, 7:30:28.2am ET 
